Trial of Docetaxel-Samarium in Patients With Hormone-Refractory Advanced Prostate Cancer

Update Il y a 2 ans
Reference: NCT00126230

  • | Country :
  • France
  • | organs :
  • -
  • | Specialty :
  • -

Extract

This is a prospective phase II trial of docetaxel-samarium in patients with hormone-refractory advanced prostate cancer who achieve a response or a stabilization to docetaxel-estramustine.


Inclusion criteria

  • Prostate cancer

Links